|
KMID : 1101420190510010026
|
|
Korean Journal of Clinical Laboratory Science
2019 Volume.51 No. 1 p.26 ~ p.33
|
|
|
Investigation of the Molecular Diagnostic Market in Animals
|
|
Park Chang-Eun
Park Sung-Ha
|
|
|
Abstract
|
|
|
|
Recently, the rapid growth of the companion animal market has led to the development of animal disease diagnosis kits. Therefore, the utility of the introduction of biomarkers for the development of animal molecular diagnostics is being reevaluated. A good biomarker should be precise and reliable, distinguish between normal and diseased states, and differentiate between different diseases. Recently reported genetic markers, tumor markers (cell free DNA, circulating tumor cells, granzyme, and skin tumors), and others (brucellosis, programmed death recovery-1, symmetric dimethylarginine, periostin, and cysteinyl leukotrien) have been developed. The biomarkers are used for risk prediction or for the screening, diagnosis, and monitoring of disease progression. The most important criteria for related biomarkers are disease specificity. Many potential biomarkers have emerged from laboratory and test studies, but they have not been validated in independent or large-scale clinical studies. Candidate biomarkers evaluate disease associations, verify the effectiveness of biomarkers for early detection and disease progression, and incorporate them into humans and animals. In the future, it will be necessary to reevaluate the utility of well-structured biomarker-based research and study the development of kits that can be used in on-site tests in accordance with the trends introduced in the diagnosis of animal diseases.
|
|
|
KEYWORD
|
|
|
Biomarkers, Companion animal, Disease progression, In vitro diagnosis, Tumor marker
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|